Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1

被引:7
|
作者
Ilkovitch, Dan [1 ]
Carrio, Roberto [1 ,2 ]
Lopez, Diana M. [1 ,2 ]
机构
[1] Univ Miami, Dept Microbiol & Immunol, Miller Sch Med, Miami, FL 33101 USA
[2] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
基金
美国国家卫生研究院;
关键词
Mucins; MUC1 secreted form; Antitumor activity; Immune-enhancing peptide; CCL2; Urokinase plasminogen activator; STATs; Myeloid-derived suppressor cells; REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; MYELOID SUPPRESSOR-CELLS; TUMOR-ASSOCIATED MACROPHAGES; INFLAMMATORY-BOWEL-DISEASE; IMMATURE DENDRITIC CELLS; SENTINEL LYMPH-NODE; PLASMINOGEN-ACTIVATOR; IN-VIVO; BREAST-CANCER;
D O I
10.1007/s12026-013-8451-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mucin 1 (MUC1) is a polymorphic type 1 transmembrane protein found on the apical surface of normal cells lining the lumen of ducts and glands. Mucins are thought to provide mucosal protection from environmental exposures and carcinogens. An altered form of the MUC1 glycoprotein, which is hypoglycosylated, is expressed in several types of human cancers. In our laboratory, we have found that transfection of a murine mammary tumor cell line with a human secreted isoform of MUC1 rendered these DA-3 cells (DA-3/sec) incapable of growing in intact BALB/c mice. In contrast, implantation of DA-3 cells transfected with the human transmembrane isoform of MUC1 (DA-3/TM), resulted in tumor formation and ultimately death of the animals, similar to the DA-3 parental line. Importantly, inoculation of the DA-3/sec cells in immunodeficient nude mice resulted in tumor formation, indicating that the MUC1/sec molecule's antitumor activity is immunologically controlled. In this review, we summarize the studies we have performed to elucidate possible mechanisms for the immune-mediated antitumor effect of MUC1/sec and/or a unique peptide present in this mucin. Understanding these mechanisms may provide new immunotherapeutic approaches that could be used to target different types of cancer.
引用
收藏
页码:70 / 80
页数:11
相关论文
共 40 条
  • [1] Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1
    Dan Ilkovitch
    Roberto Carrio
    Diana M. Lopez
    Immunologic Research, 2013, 57 : 70 - 80
  • [2] Mucin-1 (MUC1) as a promising molecular target in anticancer therapy
    Gornowicz, Agnieszka
    Bielawska, Anna
    Poplawska, Bozena
    Bielawski, Krzysztof
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2019, 73 : 53 - 64
  • [3] Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies
    Smorodinsky, N
    Weiss, M
    Hartmann, ML
    Baruch, A
    Harness, E
    Yaakobovitz, M
    Keydar, I
    Wreschner, DH
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 228 (01) : 115 - 121
  • [4] Detection of circulating mammary mucin (MUC1) and MUC1 immune complexes (MUC1-CIC) in healthy women
    Croce, MV
    Isla-Larrain, MT
    Price, MR
    Segal-Eiras, A
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (02): : 112 - 120
  • [5] Identification of mimotopes of the epithelial mucin-1 (MUC1) in non-small cell lung cancer
    Yu Qiu
    Wang Jianfei
    Cao Ruoqiong
    Zhang Yi
    Sun Yangyang
    Li Zhong
    CANCER RESEARCH, 2016, 76
  • [6] Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma
    Burton, J
    Mishina, D
    Cardillo, T
    Lew, K
    Rubin, A
    Goldenberg, DM
    Gold, DV
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3065S - 3072S
  • [7] Expression of MUC1 mucin on activated human T cells: Implications for a role of MUC1 in normal immune regulation
    Agrawal, B
    Krantz, MJ
    Parker, J
    Longenecker, BM
    CANCER RESEARCH, 1998, 58 (18) : 4079 - 4081
  • [8] Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
    Lakshminarayanan, Vani
    Thompson, Pamela
    Wolfert, Margreet A.
    Buskas, Therese
    Bradley, Judy M.
    Pathangey, Latha B.
    Madsen, Cathy S.
    Cohen, Peter A.
    Gendler, Sandra J.
    Boons, Geert-Jan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (01) : 261 - 266
  • [9] Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells
    Brockhausen, I.
    Yang, J.-M.
    Burchell, J.
    Whitehouse, C.
    European Journal of Biochemistry, 233 (02):
  • [10] Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients
    Isla Larrain, Marina T.
    Colussi, Andrea G.
    Demichelis, Sandra O.
    Barbera, Alberto
    Creton, Aldo
    Segal-Eiras, Amada
    Croce, Maria V.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2013, 28 (03): : 318 - 325